J. Gregory Cairncross

J. Gregory Cairncross's AcademicInfluence.com Rankings

Philosophy

#9838

World Rank

#13452

Historical Rank

Logic

#6796

World Rank

#8345

Historical Rank

philosophy Degrees

Download Badge

Philosophy

J. Gregory Cairncross's Degrees

Doctorate Medicine University of California, San Francisco
PhD Biomedical Sciences University of California, San Francisco

Why Is J. Gregory Cairncross Influential?

(Suggest an Edit or Addition)

(See a Problem?)

J. Gregory Cairncross's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. (2005) (16695)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. (2009) (6397)
MGMT gene silencing and benefit from temozolomide in glioblastoma. (2005) (4989)
Response criteria for phase II studies of supratentorial malignant glioma. (1990) (2337)
Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors (2000) (781)
Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. (2004) (754)
Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. (2008) (682)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. (2008) (496)
Radation therapy for brain metastases (1980) (421)
Changing paradigms--an update on the multidisciplinary management of malignant glioma. (2006) (394)
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. (2014) (354)
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets (1982) (350)
Successful chemotherapy for recurrent malignant oligodendroglioma (1988) (338)
Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma. (1989) (299)
Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. (1992) (275)
Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers (2012) (273)
Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma (2011) (273)
Which glioblastoma multiforme patient will become a long‐term survivor? A population‐based study (1999) (252)
Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. (1999) (217)
Proliferation of Human Glioblastoma Stem Cells Occurs Independently of Exogenous Mitogens (2009) (174)
A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. (1994) (160)
An in vivo patient-derived model of endogenous IDH1-mutant glioma. (2012) (159)
Selection bias, survival, and brachytherapy for glioma. (1992) (154)
Lactate dehydrogenase A silencing in IDH mutant gliomas. (2014) (151)
Malignant glioma: Who benefits from adjuvant chemotherapy? (1998) (148)
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. (2011) (145)
Successful chemotherapy for newly diagnosed aggressive oligodendroglioma (1990) (141)
Cognitive functioning in long-term survivors of high-grade glioma. (1994) (140)
Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas (1991) (138)
Anaplastic Oligodendroglial Tumors: Refining the Correlation among Histopathology, 1p 19q Deletion and Clinical Outcome in Intergroup Radiation Therapy Oncology Group Trial 9402 (2008) (138)
Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme (2008) (130)
Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma (2016) (114)
Low-grade glioma. To treat or not to treat? (1989) (111)
The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study (2007) (101)
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. (1982) (101)
IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism. (2015) (99)
Survey of treatment recommendations for anaplastic oligodendroglioma. (2007) (97)
Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1 (2017) (93)
Corticosteroid-induced magnetic resonance imaging changes in patients with recurrent malignant glioma. (1994) (91)
Identification of glial filament protein and vimentin in the same intermediate filament system in human glioma cells. (1984) (91)
On-target JAK2/STAT3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells. (2013) (91)
Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma (2011) (89)
Steroid‐induced CT changes in patients with recurrent malignant glioma (1988) (87)
Metastatic anaplastic oligodendroglioma (1989) (80)
Oligodendroglioma cell lines containing t(1;19)(q10;p10). (2010) (79)
O6-methylguanine-DNA methyltransferase regulation by p53 in astrocytic cells. (2007) (79)
Adult supratentorial low-grade glioma: long-term experience at a single institution. (2009) (78)
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression (2020) (78)
Ki-67: a prognostic factor for low-grade glioma? (2002) (76)
Amplified, overexpressed and rearranged epidermal growth factor receptor gene in a human astrocytoma cell line. (1985) (76)
Recent developments in the molecular characterization and treatment of oligodendroglial tumors. (2003) (75)
Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (1999) (74)
Salvage chemotherapy for oligodendroglioma. (1996) (70)
Sensitivity to temozolomide in brain tumor initiating cells. (2010) (69)
Prospective study of postoperative magnetic resonance imaging in patients with malignant gliomas. (1997) (69)
An intermediate filament-associated protein, p50, recognized by monoclonal antibodies (1983) (61)
Drug Insight: temozolomide as a treatment for malignant glioma—impact of a recent trial (2005) (61)
Population-Based Study of Pseudoprogression after Chemoradiotherapy in GBM (2009) (60)
Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813 (2016) (58)
Selection bias in clinical trails of anaplastic glioma (1989) (57)
Long‐Term Survivors of Glioblastoma: Statistical Aberration or Important Unrecognized Molecular Subtype? (2003) (57)
Chemotherapy for brain tumors. (1998) (55)
A phase III randomized controlled trial of short-course radiotherapy with or without concomitant and adjuvant temozolomide in elderly patients with glioblastoma (CCTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677). (2016) (53)
A novel C19MC amplified cell line links Lin28/let-7 to mTOR signaling in embryonal tumor with multilayered rosettes. (2014) (52)
Novel MSH6 Mutations in Treatment-Naïve Glioblastoma and Anaplastic Oligodendroglioma Contribute to Temozolomide Resistance Independently of MGMT Promoter Methylation (2014) (52)
Treatment of a single brain metastasis: the role of radiation following surgical resection. (1998) (51)
Initial treatment patterns over time for anaplastic oligodendroglial tumors. (2012) (51)
Monoclonal antibodies to three widely distributed human cell surface antigens. (1983) (50)
Use of peri-operative anti-epileptic drugs in patients with newly diagnosed high grade malignant glioma: a single center experience (2010) (49)
A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma (2006) (49)
Precursor States of Brain Tumor Initiating Cell Lines Are Predictive of Survival in Xenografts and Associated with Glioblastoma Subtypes (2015) (49)
Hyperpolarized 13C MR imaging detects no lactate production in mutant IDH1 gliomas: Implications for diagnosis and response monitoring (2016) (47)
Clinicopathologic Study and Review of the Literature (1993) (46)
Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin. (2013) (44)
Sterilization of cerebral metastases by radiation therapy (1979) (44)
Measuring Bias in Uncontrolled Brain Tumor Trials – to Randomize or Not to Randomize? (1997) (43)
Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity (2014) (42)
Low-grade gliomas in children: tumor volume response to radiation. (1998) (41)
Dual mTORC1/2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival (2014) (41)
Inactivation of p53 sensitizes U87MG glioma cells to 1,3-bis(2-chloroethyl)-1-nitrosourea. (2001) (41)
Challenges in the design and conduct of phase III brain tumor therapy trials (1997) (40)
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain (1996) (40)
Pharmaceutical‐mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide (2005) (39)
Chemosensitive gliomas in adults: which ones and why? (1997) (38)
Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. (1993) (38)
Spontaneous loss of heterozygosity leading to homozygous R132H in a patient-derived IDH1 mutant cell line. (2013) (35)
Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin (2005) (35)
Post-Surgical Contrast Enhancement Mimicking Residual Brain Tumour (1985) (35)
Treatment of oligodendroglioma: an update. (1999) (35)
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: long-term follow-up. (2006) (34)
2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas. (2018) (34)
Chemotherapy for oligodendroglioma. Progress report. (1991) (34)
Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas (2008) (34)
Malignant glioma--timing of response to radiation therapy. (1993) (32)
CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
PCV for Oligodendroglial Tumors: In Search of Prognostic Factors for Response and Survival (2001) (31)
Absence of hereditary mutations in exons 5 through 9 of the p53 gene and exon 24 of the neurofibromin gene in families with glioma (1994) (31)
Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments (2019) (29)
Adjuvant Chemotherapy for Adults with Malignant Glioma: A Systematic Review (2007) (29)
Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors (2018) (29)
Radiation therapy of brain metastases. (1979) (29)
Glioma therapies: how to tell which work? (2003) (27)
The practical management of low-grade primary brain tumors (1999) (26)
O6-Methylguanine-DNA Methyltransferase in Tumors and Cells of the Oligodendrocyte Lineage (1995) (26)
Treatment of malignant glioma in adults. (1995) (25)
High-dose Chemotherapy with Stem Cell Rescue as Initial Therapy for Anaplastic Oligodendroglioma (2003) (25)
Multicenter phase II study of temozolomide and myeloablative chemotherapy with autologous stem cell transplant for newly diagnosed anaplastic oligodendroglioma (2017) (24)
Low-grade gliomas in children: tumor volume response to radiation. (1998) (24)
Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity. (2022) (24)
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts (2018) (24)
CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III Randomized Study of RT vs. RT+TMZ vs. TMZ for Newly Diagnosed 1p/19q-Codeleted Anaplastic Oligodendroglial Tumors. Analysis of Patients Treated on the Original Protocol Design (PL02.005) (2016) (23)
DNA hypermethylation and 1p Loss silence NHE‐1 in oligodendroglioma (2012) (23)
Surgical management of incidentally discovered diffusely infiltrating low-grade glioma. (2017) (23)
Do epileptic seizures predict outcome in patients with oligodendroglioma? (2011) (22)
Loss of Heterozygosity Analysis of Chromosomes 9, 10 and 17 in Gliomas in Families (1995) (22)
Phase II diaziquone-based chemotherapy trials in patients with anaplastic supratentorial astrocytic neoplasms. (1987) (21)
A better way to find tumor in the CSF? (2002) (20)
Complications of Chemotherapy (1985) (20)
Comparison of metastatic properties of a variety of mouse, rat, and human cells in assays in nude mice and chick embryos. (1990) (20)
Chemotherapy plus radiotherapy (CT-RT) versus RT alone for patients with anaplastic oligodendroglioma: Long-term results of the RTOG 9402 phase III study. (2012) (20)
Understanding low-grade glioma (2000) (18)
Acetazolamide therapy for symptomatic plateau waves in patients with brain tumors. Report of three cases. (2002) (18)
Response and control: lessons from oligodendroglioma. (1995) (17)
O(6)-methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes. (1999) (17)
Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. (2014) (16)
Neuro-Oncology: Primary Malignant Brain Tumors (1991) (16)
A phase II study of intensified chemotherapy alone as initial treatment for newly diagnosed anaplastic oligodendroglioma: an interim analysis (2008) (15)
Surgery for single brain metastasis. (1990) (15)
On-target JAK 2 / STAT 3 inhibition slows disease progression in orthotopic xenografts of human glioblastoma brain tumor stem cells (2013) (14)
A PHASE III RANDOMIZED CONTROLLED TRIAL OF SHORT-COURSE RADIOTHERAPY WITH OR WITHOUT CONCOMITANT AND ADJUVANT TEMOZOLOMIDE IN ELDERLY PATIENTS WITH GLIOBLASTOMA (NCIC CTG CE.6, EORTC 26062-22061, TROG 08.02, NCT00482677) (2014) (14)
Cerebral herniation in patients receiving cisplatin (2004) (14)
Five novel cell surface antigens of CNS neoplasms (1989) (13)
p53‐dependent up‐regulation of CDKN1A and down‐regulation of CCNE2 in response to beryllium (2016) (13)
Development of a peptide-based delivery platform for targeting malignant brain tumors. (2020) (12)
The dose–volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection (2007) (12)
Diffuse bilateral cerebral astrocytomas with atypical neuroimaging studies. (1994) (12)
Metastasis to the Central Nervous System (1989) (11)
A phase I trial of intratumoral (i.t.) administration of reovirus in patients with histologically confirmed recurrent malignant gliomas (MGs). (2006) (11)
Acute parotitis and hyperamylasemia following whole‐brain radiation therapy (1980) (11)
Temozolomide and seizure outcomes in a randomized clinical trial of elderly glioblastoma patients (2020) (10)
Bihemispheric malignant glioma: One size does not fit all (1998) (10)
O 6-Methylguanine-DNA Methyltransferase Regulation by p 53 in Astrocytic Cells (2007) (10)
Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study (1990) (10)
Contrast Enhancing Lesions in Progressive Multifocal Leukoencephalopathy: A Clinicopathological Correlation (1987) (9)
Results of NRG oncology/RTOG 9813: A phase III randomized study of radiation therapy (RT) and temozolomide (TMZ) versus RT and nitrosourea (NU) therapy for anaplastic astrocytoma (AA). (2015) (9)
Leptomeningeal disease in oligodendroglial tumors: a population-based study (2011) (9)
Low-Grade Gliomas: To Treat or Not to Treat?: A Reply (1990) (8)
Oligodendroglioma: a new chemosensitive tumor. (1990) (8)
Cognition in survivors of high-grade glioma. (1998) (7)
Texture analysis for non-invasive identification of brain tumor genotype from MRI (2005) (7)
A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. (1996) (7)
Proceedings of the Comprehensive Oncology Network Evaluating Rare CNS Tumors (NCI-CONNECT) Oligodendroglioma Workshop. (2019) (7)
In Vitro Modeling of GBM Initiation using PDGF-AA and P53-Null Neural Progenitors. (2020) (7)
PARP inhibition suppresses the emergence of temozolomide resistance in a model system (2020) (6)
Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors (2022) (6)
Inactivation of p 53 Sensitizes U 87 MG Glioma Cells to 1 , 3-bis ( 2-Chloroethyl )-1-nitrosourea 1 (2001) (5)
A TITE-CRM phase I/II study of disulfiram and copper with concurrent radiation therapy and temozolomide for newly diagnosed glioblastoma. (2019) (4)
NEURO/MEDICAL ONCOLOGY (2013) (4)
Wild-type p53 renders mouse astrocytes resistant to 1,3-Bis(2-chloroethyl)-1-nitrosourea despite the absence of a p53-dependent cell cycle arrest [corrected]. (1996) (4)
ATCT-12RESULTS OF NRG ONCOLOGY/RTOG 9813- A PHASE III RANDOMIZED STUDY OF RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) VERSUS RT AND NITROSOUREA (NU) THERAPY FOR ANAPLASTIC ASTROCYTOMA (AA) (2015) (3)
Special Article Glioma Classification A Molecular Reappraisal (2001) (3)
Malignant properties of P635 glioma are independent of glial fibrillary acidic protein expression (1991) (3)
Loss of CIC promotes mitotic dysregulation and chromosome segregation defects (2019) (3)
Regulation of neural stem cell fate by the transcriptional repressor Capicua (2018) (2)
EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
Hyperthermia and brachytherapy for glioma--will cooler heads prevail? (1992) (2)
Phase II study of tiazofurin in gliomas in adults (1993) (2)
ACTR-13. FINAL RESULTS WITH CHEMORADIOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIAL TUMORS FROM NRG ONCOLOGY/RTOG 9402 (2019) (2)
Malignant Glioma: Viewpoint—Chemotherapy (2015) (1)
Abstract 2524: STAT3 is a key regulator of an “EMT-like” process mediated by Slug in GBM (2016) (1)
Treatment of oligodendrogliomas. (1989) (1)
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG08.02) randomized clinical trial (2021) (1)
Imaging Molecular Signatures in Oligodendroglioma (2004) (1)
Radiation therapy (RT) alone vs intensive procarbazine-CCNU-vincristine (I-PCV) chemotherapy followed by radiation therapy for anaplastic oligodendroglioma (AO) and mixed oligo-astrocytoma (MOA): Results of radiation therapy oncology group (RTOG) - intergroup protocol 94–02 (2004) (1)
Neurological emergencies in cancer patients. (1983) (1)
Low-grade glioma: the case for delayed surgery. (1995) (1)
Separating the wheat from the chaff (2010) (1)
Acknowledgement of Reviewers 2012 (2013) (1)
MALIGNANT GLIOMA : WHO BENEFITS FROM ADJUVANT CHEMOTHERAPY. AUTHORS' REPLY (1999) (1)
Cell Density‐Dependent Glial Filament Expression in a Human Astrocytoma Clonal Cell Line a (1985) (1)
21 Inhibiting PARP-1 to restore temozolomide sensitivity and prevent resistance in glioblastoma (2018) (1)
Medical and Neuro-Oncology (2010) (1)
Chemotherapy for malignant gliomas. (1996) (0)
Malignant Glioma: Chemotherapy Perspective (2008) (0)
CS-04STAT3 INVOLVEMENT IN AN EMT-LIKE PROCESS IN GLIOBLASTOMA BRAIN TUMOR INITIATING CELLS (2014) (0)
703Delayed radiotherapy in the management of adult supratentorial low-grade glioma: Importance of histology, not timing of radiation (1996) (0)
An Intermediate Filament-associated Protein , Recognized by Monoclonal Antibodies p 50 , (2002) (0)
CBIO-21. STAT3 REGULATES AN SL/PL TRANSITION IN BTICs THROUGH AN EMT-LIKE PROCESS MEDIATED BY SLUG (2016) (0)
Teaching NeuroImages: Collet-Sicard syndrome and hearing loss with glomus jugulotympanicum (2019) (0)
Reply (1986) (0)
In the beginning: PDGFA and the genesis of GBM. (2021) (0)
PATH-11. PDGFA INITIATES ABERRANT MITOSIS AND MALIGNANT TRANSFORMATION OF NEURAL PROGENITOR CELLS (2021) (0)
Mitogen-Induced Defective Mitosis Transforms Neural Progenitor Cells (2023) (0)
DRES-04. CHARACTERIZATION OF A MODEL OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA (2018) (0)
TMOD-02. A MODEL OF THE INITIATION AND GENOMIC LANDSCAPE OF GLIOBLASTOMA (GBM) (2019) (0)
Cancer Therapy : Preclinical Dual mTORC 1 / 2 Blockade Inhibits Glioblastoma Brain Tumor Initiating Cells In Vitro and In Vivo and Synergizes with Temozolomide to Increase Orthotopic Xenograft Survival (2014) (0)
CARCINOMATOSIS AND CONCURRENT BACTERIAL MENINGITIS IN A PATIENT WITH ESOPHAGEAL ADENOCARCINOMA : A CASE REPORT (2011) (0)
STMC-31. STIMULATION OF MICROGLIA AND MACROPHAGES AND GROWTH ATTENUATION OF BRAIN TUMOR-INITIATING CELLS WITH TUMOR NECROSIS FACTOR-ALPHA (2016) (0)
Capicua regulates neural stem cell proliferation and lineage specification through control of Ets factors (2019) (0)
Response to Weltman and Fleury Malheiros, re Lassman et al. (2012) (0)
2011 Jeremy Jass Prize for Research Excellence in Pathology (2012) (0)
Reply (1999) (0)
A decade of progress (2000) (0)
Role of surgery for high-grade astrocytomas. (1991) (0)
DRES-06. PREVENTING THE EMERGENCE OF TEMOZOLOMIDE RESISTANCE IN GLIOBLASTOMA BY PARP-1 INHIBITION (2018) (0)
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies : Identification of astrocytoma subsets ( hybridoma / differentiation antigens / glial fibrillary acidic protein ) (2003) (0)
The dose–volume interaction in adult supratentorial low-grade glioma: higher radiation dose is beneficial among patients with partial resection (2001) (0)
Next generation sequencing of oligodendroglioma – a work in progress (2011) (0)
Cancer in the Nervous System (1996) (0)
Beyond Conventional Models: Recreating the Initiation, Evolution, and Genome of GBM (2019) (0)
LAB-TUMOR MODELS (IN VIVO/IN VITRO) (2012) (0)
NCOG-12. COGNITIVE FUNCTION (CF) & QUALITY OF LIFE (QOL) IN PATIENTS TREATED WITH PROCARBAZINE, CCNU, & VINCRISTINE (PCV) + RADIOTHERAPY (RT) VS. RT FOR ANAPLASTIC OLIGODENDROGLIOMA (AO) ON NRG RTOG TRIAL 9402 (2021) (0)
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trial (2022) (0)
Abstracts for the Tenth International Conference on Brain Tumour Research and Therapy (2005) (0)
The Biology Behind Imaging Molecular Signatures in Oligodendroglioma Commentary on Walker et al . , pages 7182 – 7191 (2004) (0)
Acknowledgement of reviewers 2016 and 2017 (2018) (0)
Phase II trial of temozolomide (TMZ) followed by myeloablative chemotherapy with autologous peripheral blood progenitor cell rescue (APBPCR) for newly diagnosed anaplastic oligodendroglioma: An Oligodendroglioma Study Group trial. (2009) (0)
CS-04. STAT3 INVOLVEMENT IN AN EMT-LIKE PROCESS IN GLIOBLASTOMA BRAIN TUMOR INITIATING CELLS (2014) (0)
Metabolic profiling of gliomas reveals distinct subgroups of tumors independent of IDH mutation status (2018) (0)
Multi-omic analysis of CIC’s functional networks reveals novel interaction partners and a potential role in mitotic fidelity (2023) (0)
Malignant glioma: Who benefits from adjuvant chemotherapy? (multiple letters) (1999) (0)
GLIOMA SPECIFIC PEPTIDES: A PLATFORM FOR MOLECULAR IMAGING AND THERAPEUTIC TARGETING (2014) (0)
LAB-STEM CELLS (2012) (0)
Interferon beta for malignant glioma. (1992) (0)
A PHASE III RANDOMIZED PROSPECTIVE TRIAL OF EXTERNAL BEAM RADKlTHERAPY, MITOMYCIN C, CARMUSTINE, AND 6-~RCA~~NE FOR THE TREATMENT OF ADULTS WITH ANAPLAS'IK GLIOMA OF THE BRAIN (1995) (0)
Genetic landscape of extreme responders with anaplastic oligodendroglioma: NRG Oncology/RTOG 9402. (2016) (0)
CBIO-42DOWN REGULATION OF PYRUVATE DEHYDROGENASE ACTIVITY IS ESSENTIAL FOR CELL PROLIFERATION IN IDH1 MUTANT GLIOMA CELLS. (2015) (0)
Molecular Determinants of Prognosis and Evolution in Diffuse-Lower Grade Astrocytomas (2020) (0)
GENO-10LOSS OF IDH MUTATION IN PATIENT-DERIVED BRAIN TUMOR INITIATING CELLS (2015) (0)
CJN volume 22 issue 2 Cover and Front matter (1995) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With J. Gregory Cairncross?

J. Gregory Cairncross is affiliated with the following schools:

University of Calgary